Use of genomic signatures in therapeutics development in oncology and other diseases

Pharmacogenomics Journal

Volumn 6, Issue 3, 2006, Pages 166-173

  Simon, R ^a   Wang, S J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical trial; Gene expression; Genomic signature; Oncology; Study design; Validation

Indexed keywords

ABACAVIR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; HLA B ANTIGEN; PLACEBO; TRASTUZUMAB;

ACCURACY; ARTICLE; BIOASSAY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL TRIAL; COLON CARCINOMA; DATA ANALYSIS; DISEASE SEVERITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; GERM LINE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MATERIALS HANDLING; MEDICAL DECISION MAKING; METHODOLOGY; ONCOLOGY; OUTCOME ASSESSMENT; PATIENT CODING; PATIENT SELECTION; PHARMACOGENOMICS; POPULATION GENETICS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CLINICAL TRIALS; MEDICAL ONCOLOGY; PROSPECTIVE STUDIES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33646047815     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500349     Document Type: Article

References (25)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. J Am Med Assoc 1998; 279: 1200-1205.
2. Evans BJ, Flockhart DA, Meslin EM. Creating incentives for genomic research to improve targeting of therapies. Nat Med 2004; 10(12): 1289-1291.
3. Group BDW. Commentary: BiomarkPrs and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therapeut 2001; 69(3): 89-95.
4. Tsai CA, Wang SJ, Chen DT, Chen JJ, Tsai CA. Sample size for gene expression microarray experiments. Bioinformatics 2004; 21: 1502-1508.
5. Simon R. Diagnostic and prognostic prediction using gene expression profiles in high dimensional microarray data. Br J Cancer 2003; 89: 1599-1604.
6. Simon RM, Korn EL, McShane LM, Radmacher MD, Wright GW, Zhao Y. Design and Analysis of DNA Microarray Investigations. Springer: New York, 2003.
7. Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol 2004; 15: 1731-1737.
8. Dudoit S, Fridlyand J, Speed TP. Comparison of discrimination methods for classification of tumors using gene expression data. J Am Stat Assoc 2002; 97: 77-87.
9. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
10. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the analysis of DNA microarray data: Class prediction methods. J Natl Cancer Instit 2003; 95: 14-18.
11. van'tVeer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Branigan BW. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
13. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
14. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004; 10: 6759-6763.
15. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353(2): 133-144.
16. Roses AD. Pharmacogenetics and drug development: The path to safer and more effective drugs. Nat Rev Genet 2004; 5: 645-656.
17. Bonner J, Giralt J, Harari PM, Cohen C, Jones C, Sur RK et al. Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol 2004; 22: 5507.
18. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005; 23(9): 2020-2027.
19. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials. Oncology 2001; 61 (Suppl 2): 14-21.
20. Eiermann W. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data. Ann Oncol 2001; 12(Suppl 1): S57-S62.
21. Weiss ST, Silverman EK, Palmer LJ. Case-control association studies in pharmacogenetics. Pharmacogenomics J 2001; 1: 157-158.
22. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65: 220-228.
23. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-1122.
24. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C et al. Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor avacavir. Lancet 2002; 359: 727-732.
25. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some but not all populations. Pharmacogenomics 2004; 5(2): 203-211.